Synchron
Manufacturing · Georgia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Tbs 0177 Oo Chavchavadze Ave, GeorgiaPhone Number
+995 577122104Website
www.synchron.geRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Synchron
Synchron, Inc. is a neurovascular bioelectronics medicine company developing bloodstream-enabled solutions for previously-untreatable nervous system conditions. The company is pioneering the field of interventional neuromodulation and developing the world's first motor neuroprosthesis, the Stentrode, a brain-computer interface in clinical trials to evaluate its ability to help paralyzed patients regain the ability to regain functional independence. The company is also developing endovascular neuromodulation solutions for the potential treatment of Parkinson's disease, epilepsy, depression and hypertension, among other disorders. Development of this technology platform was spun out of the University of Melbourne and has been funded in part through grants from the U.S. Defense Advanced Research Projects Agency (DARPA) and U.S. Department of Defense (DoD). The technology was publicly endorsed by then-President Barack Obama as "technology that has the potential to transform lives of our woRead more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Synchron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Synchron is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Synchron launches new products
Synchron, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Synchron had a recent Job posting/layoffs
Earning: See what the market has to say on Synchron recently announced quarterly report
Funding: Get notified immidiatlly once Synchron has new funding data
Check if Synchron has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Synchron
Recommended Actions
Find VP level buyers at Synchron
Find 3 more new buyers
Company Profile Activity
Activity Insights
Synchron is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Synchron is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Synchron.
Synchron financials insights
Gather financial insights about Synchron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$10M
2021
Series B
$40M
Synchron Tech Stack
A closer look at the technologies used by Synchron
See more technologies
Synchron News & Media
Synchron’s Stentrode Brain-Computer Interface Receives Breakthrough Device Designation from FDA
SAN FRANCISCO & NEW YORK & MELBOURNE, Australia--(BUSINESS WIRE)--Synchron, a neurovascular bioelectronics medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for Stentrode, a fully-implantable medical device that can translate brain activity or stimulate the nervous system from the inside of a blood vessel, without the need for open brain surgery. The device, which has already been implanted in patients with upper-limbSynchron Secures Further Funding from the Australian Government to Advance Commercialization of Stentrode
SAN FRANCISCO & NEW YORK CITY & MELBOURNE, Australia--(BUSINESS WIRE)--Synchron Secures Further Funding from the Australian Government to Advance Commercialization of Stentrode.Synchron Achieves First Successful Human Implantation of Brain Computer Interface
SAN FRANCISCO and NEW YORK CITY and MELBOURNE, Australia, Sept. 20 2019 /PRNewswire/ -- Synchron Inc. today announced the first successful clinical implantation of the Stentrode®, a minimally-invasive neural interface technology, a component of the Synchron Brain-Computer Interface. This...Study Published in Nature Biomed Shows Promise for Patients with Neurological Conditions including Parkinson's disease, Depression and Epilepsy
NEW YORK and SAN FRANCISCO, Dec. 3, 2018 /PRNewswire/ -- Synchron Inc., a company developing minimally invasive neural interface technology, today announced data demonstrating the feasibility of minimally-invasive techniques to enable focal brain stimulation has been published in the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Synchron
Sign Up For FreeTo access detailed company insights
Synchron, Inc. is a neurovascular bioelectronics medicine company developing bloodstream-enabled solutions for previously-untreatable nervous system conditions. The company is pioneering the field of interventional neuromodulation and developing the world's first motor neuroprosthesis, the Stentrode, a brain-computer interface in clinical trials to... Read More
